These mutations are associated with an augmentation of the protein levels of RANKL, the ligand that interacts with RANK and induces an increase in the activity of osteoclasts, resulting in a worsening of the osteoporosis condition of the patients [35]. This evidence concerns the gene TNFRSF11A and osteoporosis.